Stifel Reiterates Buy Rating, $35 PT on Kinnate Biopharma (KNTE), "Remain Optimistic into KIN-2787 Monotherapy Data"
Tweet Send to a Friend
Stifel analyst Ben Burnett reiterated a Buy rating and $35.00 price target on Kinnate Biopharma (NASDAQ: KNTE), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
